Wellgistics Health Announces Reverse Stock Split
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX) approved a 1-for-50 reverse stock split of its common stock, effective 12:01 a.m. ET on May 26, 2026. The move is intended to raise the share price and help regain compliance with Nasdaq’s minimum bid requirement.
The split will reduce outstanding shares from about 125.7 million to about 2.5 million, with fractional shares rounded up, while authorized share counts and economic rights under options, warrants, and convertibles are proportionally adjusted.
AI-generated analysis. Not financial advice.
Positive
- 1-for-50 reverse split aims to regain Nasdaq minimum bid price compliance
- Outstanding common shares reduced from ~125,671,251 to ~2,513,425
- Fractional shares will be rounded up to the nearest whole share
- Proportional adjustments preserve economic value of options, warrants, and convertibles
- No action required for book-entry and broker-held shareholders
Negative
- Company needs to regain compliance with Nasdaq’s minimum bid price requirement
News Market Reaction – WGRX
On the day this news was published, WGRX declined 17.05%, reflecting a significant negative market reaction. Argus tracked a peak move of +61.2% during that session. Argus tracked a trough of -38.1% from its starting point during tracking. Our momentum scanner triggered 46 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $21.28M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
WGRX fell 25.65% while peers showed mixed moves: PETS up 1.83%, HITI up 1.69%, HKPD down 3.6%, SCNX down 1.73%, SSY up 9.31%. Momentum data also flags both up and down moves among peers, supporting a stock-specific reaction to WGRX developments.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 20 | Strategic AI deal | Positive | -25.6% | Binding term sheet to form DelivMeds AI via multiple acquisitions. |
| May 19 | Earnings update | Positive | -25.6% | Q1 2026 revenue growth and narrowed net operating loss. |
| May 15 | Earnings date notice | Neutral | +108.4% | Announcement of upcoming Q1 2026 financial results release date. |
| May 14 | Planned acquisition | Positive | -3.1% | LOI to acquire WellCare Today and integrate monitoring platform. |
| May 13 | Partnership pilot | Positive | +23.1% | Pilot MSO collaboration targeting CCM and RPM market expansion. |
Recent WGRX news often saw negative price reactions even to seemingly constructive updates, with only one of the last five items showing a price move aligned with the apparent news tone.
Over the last week, WGRX issued multiple strategic and financial updates, including an MSO collaboration on May 13, a planned digital-health acquisition on May 14, and Q1 2026 earnings on May 19. A large AI/acquisition term sheet followed on May 20. Despite generally growth-focused headlines and revenue improvements, four of these five events saw negative or contrary price reactions, framing today’s reverse split within an already pressured trading backdrop.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-04-15 registers up to $200,000,000 of securities for issuance over time, with 0 recorded takedowns so far. This gives the company significant capital-raising capacity alongside the reverse split, which can be used for general corporate purposes as disclosed.
Market Pulse Summary
The stock dropped -17.1% in the session following this news. The decline reflects market sensitivity to reverse stock splits by companies already trading far below prior highs. A 1-for-50 consolidation combined with an existing $200,000,000 shelf registration could have raised concerns about future dilution and listing risk, especially after several recent news events where price action diverged from positive operational updates. Subsequent financing terms and balance-sheet progress would have been key to determining whether weakness persisted.
Key Terms
reverse stock split financial
cusip financial
convertible securities financial
AI-generated analysis. Not financial advice.
TAMPA, FL / ACCESS Newswire / May 20, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its board of directors approved the Company's 1-for-50 reverse stock split (the "Reverse Split") of the Company's common stock, par value
The Reverse Split will legally take effect at 12:01 a.m. Eastern Time, on May 26, 2026. The Reverse Split is intended to increase the per share trading price of the Common Stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-50 Reverse Split will automatically convert every 50 current shares of the Company's Common Stock into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Split. Any fractional share of Common Stock that would otherwise result from the Reverse Split will be rounded up to the nearest whole share.
The Reverse Split will reduce the number of shares of outstanding Common Stock from approximately 125,671,251 to approximately 2,513,425 shares of Common Stock. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split.
Additional information regarding the Reverse Split is available in the Company's definitive information statement originally filed with the U.S. Securities and Exchange Commission (SEC) on April 3, 2026.
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.
Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire